caffeine has been researched along with Neurodegenerative Diseases in 31 studies
Neurodegenerative Diseases: Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, the need to adjust the CF dosage to individuals, because some people are more sensitive to drugs than others, may constituted a limit to the CF effectiveness." | 6.61 | Protective Effects of the Caffeine Against Neurodegenerative Diseases. ( Ficarra, S; Galtieri, A; Russo, A; Tellone, E, 2019) |
| " The seemingly paradoxical use of both adenosine receptor agonists and antagonists as neuroprotective agents has been attributed to differences in dosage levels, drug delivery method, extracellular concentration of excitatory neurotransmitters and stage of disease progression." | 6.50 | Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. ( Díaz-Ríos, M; Rivera-Oliver, M, 2014) |
| "High uric acid (UA levels have been correlated with a reduced risk of many neurodegenerative diseases through mechanisms involving chelating Fenton reaction transitional metals, antioxidant quenching of superoxide and hydroxyl free radicals, and as an electron donor that increases antioxidant enzyme activity (e." | 4.91 | The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders. ( Camandola, S; Cutler, RG; Edelhauser, MA; Malott, KF; Mattson, MP, 2015) |
| " Here we have analyzed naturally occurring MTXs caffeine, theobromine, theophylline, and the synthetic MTXs pentoxifylline and propentofylline also used as drugs in different neuroblastoma cell lines." | 4.12 | Methylxanthines Induce a Change in the AD/Neurodegeneration-Linked Lipid Profile in Neuroblastoma Cells. ( Bachmann, CM; Griebsch, LV; Grimm, HS; Grimm, MOW; Hartmann, T; Janitschke, D; Lauer, AA; Pilz, SM; Theiss, EL; Winkler, J, 2022) |
| "The purine alkaloid caffeine is the most widely consumed psychostimulant drug in the world and has multiple beneficial pharmacological activities, for example, in neurodegenerative diseases." | 4.02 | The Medicinal Chemistry of Caffeine. ( Arifi, S; Faudone, G; Merk, D, 2021) |
| "Patients with Parkinson's disease can apparently benefit from caffeine consumption, as a number of experimental and clinical studies have already shown." | 3.01 | [Caffeine, Chocolate and Adenosine A2A Receptor Antagonists in the Treatment of Parkinson's Disease]. ( Reichmann, H, 2023) |
| " However, the need to adjust the CF dosage to individuals, because some people are more sensitive to drugs than others, may constituted a limit to the CF effectiveness." | 2.61 | Protective Effects of the Caffeine Against Neurodegenerative Diseases. ( Ficarra, S; Galtieri, A; Russo, A; Tellone, E, 2019) |
| "Theanine can inhibit the glutamate receptors and regulate the extracellular concentration of glutamine, presenting neuroprotective effects." | 2.58 | Neuroprotective Effects and Mechanisms of Tea Bioactive Components in Neurodegenerative Diseases. ( Chen, SQ; Liang, YR; Lu, JL; Ma, YX; Wang, ZS; Zhang, W; Zheng, XQ, 2018) |
| "Caffeine is a pharmacologically promising substance that deserves big consideration in the current research and development." | 2.52 | The perspective of caffeine and caffeine derived compounds in therapy. ( Pohanka, M, 2015) |
| " The seemingly paradoxical use of both adenosine receptor agonists and antagonists as neuroprotective agents has been attributed to differences in dosage levels, drug delivery method, extracellular concentration of excitatory neurotransmitters and stage of disease progression." | 2.50 | Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. ( Díaz-Ríos, M; Rivera-Oliver, M, 2014) |
| "Caffeine has also effects on the reward system but it seems that this effect does not involve dopaminergic system." | 2.50 | Molecular and pharmacodynamic interactions between caffeine and dopaminergic system. ( Coman, O; Fulga, I; Ghiță, I; Segărceanu, A; Voiculescu, M, 2014) |
| "Neurodegenerative disorders are some of the most feared illnesses in modern society, with no effective treatments to slow or halt this neurodegeneration." | 2.47 | Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies. ( Chen, JF; Chern, Y, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (58.06) | 24.3611 |
| 2020's | 13 (41.94) | 2.80 |
| Authors | Studies |
|---|---|
| Koch, P | 1 |
| Akkari, R | 1 |
| Brunschweiger, A | 1 |
| Borrmann, T | 1 |
| Schlenk, M | 1 |
| Küppers, P | 1 |
| Köse, M | 1 |
| Radjainia, H | 1 |
| Hockemeyer, J | 1 |
| Drabczyńska, A | 1 |
| Kieć-Kononowicz, K | 1 |
| Müller, CE | 1 |
| Rodak, K | 1 |
| Kokot, I | 1 |
| Kratz, EM | 1 |
| Merighi, S | 1 |
| Borea, PA | 1 |
| Varani, K | 1 |
| Vincenzi, F | 1 |
| Jacobson, KA | 1 |
| Gessi, S | 1 |
| Sharma, K | 1 |
| Fallon, SJ | 1 |
| Davis, T | 1 |
| Ankrett, S | 1 |
| Munro, G | 1 |
| Christopher, G | 1 |
| Coulthard, E | 1 |
| Janitschke, D | 2 |
| Lauer, AA | 2 |
| Bachmann, CM | 2 |
| Winkler, J | 1 |
| Griebsch, LV | 1 |
| Pilz, SM | 1 |
| Theiss, EL | 1 |
| Grimm, HS | 2 |
| Hartmann, T | 2 |
| Grimm, MOW | 2 |
| Pohanka, M | 2 |
| Reichmann, H | 1 |
| Ruggiero, M | 1 |
| Calvello, R | 1 |
| Porro, C | 1 |
| Messina, G | 1 |
| Cianciulli, A | 1 |
| Panaro, MA | 1 |
| Singh, A | 3 |
| Williams, S | 3 |
| Calabrese, A | 3 |
| Riha, R | 3 |
| Machado, DG | 1 |
| Lara, MVS | 1 |
| Dobler, PB | 1 |
| Almeida, RF | 1 |
| Porciúncula, LO | 1 |
| Colombo, R | 2 |
| Papetti, A | 2 |
| Faudone, G | 1 |
| Arifi, S | 1 |
| Merk, D | 1 |
| Kolahdouzan, M | 1 |
| Hamadeh, MJ | 1 |
| Grosso, G | 1 |
| Godos, J | 1 |
| Galvano, F | 1 |
| Giovannucci, EL | 1 |
| Gökcen, BB | 1 |
| Şanlier, N | 1 |
| Tellone, E | 1 |
| Galtieri, A | 1 |
| Russo, A | 1 |
| Ficarra, S | 1 |
| Chen, SQ | 1 |
| Wang, ZS | 1 |
| Ma, YX | 1 |
| Zhang, W | 1 |
| Lu, JL | 1 |
| Liang, YR | 1 |
| Zheng, XQ | 1 |
| James, JE | 1 |
| Nepozitek, J | 1 |
| Dostalova, S | 1 |
| Dusek, P | 2 |
| Kemlink, D | 1 |
| Prihodova, I | 1 |
| Ibarburu Lorenzo Y Losada, V | 1 |
| Friedrich, L | 1 |
| Bezdicek, O | 1 |
| Nikolai, T | 1 |
| Perinova, P | 1 |
| Dall'Antonia, I | 1 |
| Ruml, M | 1 |
| Ruzicka, E | 1 |
| Sonka, K | 1 |
| Rivera-Oliver, M | 1 |
| Díaz-Ríos, M | 1 |
| Kim, J | 2 |
| Shim, J | 1 |
| Lee, CY | 1 |
| Lee, KW | 1 |
| Lee, HJ | 1 |
| Cutler, RG | 1 |
| Camandola, S | 1 |
| Malott, KF | 1 |
| Edelhauser, MA | 1 |
| Mattson, MP | 1 |
| Voiculescu, M | 1 |
| Ghiță, I | 1 |
| Segărceanu, A | 1 |
| Fulga, I | 1 |
| Coman, O | 1 |
| Oñatibia-Astibia, A | 1 |
| Franco, R | 1 |
| Martínez-Pinilla, E | 1 |
| Madeira, MH | 1 |
| Boia, R | 1 |
| Ambrósio, AF | 1 |
| Santiago, AR | 1 |
| de Mendonça, A | 1 |
| Cunha, RA | 1 |
| Chen, JF | 1 |
| Chern, Y | 1 |
| Strydom, B | 1 |
| Bergh, JJ | 1 |
| Petzer, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Early Use of Caffeine Citrate in Preterm Neonates Needing Respiratory Support.[NCT04001712] | Phase 3 | 54 participants (Actual) | Interventional | 2019-04-05 | Completed | ||
| Effects of Caffeine and Coffee on Resting Metabolic Rate, Comparing Normal Weight Men to Obese Men[NCT02751840] | Phase 3 | 33 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 reviews available for caffeine and Neurodegenerative Diseases
| Article | Year |
|---|---|
Caffeine as a Factor Influencing the Functioning of the Human Body-Friend or Foe?
Topics: Adolescent; Adult; Analgesics; Animals; Antioxidants; Caffeine; Cardiovascular System; Central Nervo | 2021 |
A
Topics: Adenosine A2 Receptor Antagonists; Alzheimer Disease; Amyloid beta-Peptides; Animals; Caffeine; Huma | 2022 |
Role of Caffeine in the Age-related Neurodegenerative Diseases: A Review.
Topics: Acetylcholinesterase; Alkaloids; Caffeine; Coffee; Dopamine; Glutamates; Humans; Neurodegenerative D | 2022 |
[Caffeine, Chocolate and Adenosine A2A Receptor Antagonists in the Treatment of Parkinson's Disease].
Topics: Adenosine A2 Receptor Antagonists; Animals; Caffeine; Chocolate; Humans; Neurodegenerative Diseases; | 2023 |
Neurodegenerative Diseases: Can Caffeine Be a Powerful Ally to Weaken Neuroinflammation?
Topics: Caffeine; Coffee; Humans; Neurodegenerative Diseases; Neuroinflammatory Diseases | 2022 |
Decaffeinated coffee and its benefits on health: focus on systemic disorders.
Topics: Caffeine; Coffee; Humans; Neurodegenerative Diseases | 2021 |
Methylxanthines and Neurodegenerative Diseases: An Update.
Topics: Alzheimer Disease; Animals; Caffeine; Coffee; Humans; Multiple Sclerosis; Neurodegenerative Diseases | 2021 |
The neuroprotective effects of caffeine in neurodegenerative diseases.
Topics: Animals; Caffeine; Humans; Neurodegenerative Diseases; Neuroprotective Agents | 2017 |
Coffee, Caffeine, and Health Outcomes: An Umbrella Review.
Topics: Caffeine; Cardiovascular Diseases; Coffee; Diabetes Mellitus, Type 2; Female; Humans; Male; Neoplasm | 2017 |
Coffee consumption and disease correlations.
Topics: Caffeine; Cardiovascular Diseases; Chlorogenic Acid; Coffee; Diabetes Mellitus, Type 2; Diterpenes; | 2019 |
Protective Effects of the Caffeine Against Neurodegenerative Diseases.
Topics: Animals; Caffeine; Humans; Molecular Structure; Neurodegenerative Diseases; Neuroprotective Agents | 2019 |
Neuroprotective Effects and Mechanisms of Tea Bioactive Components in Neurodegenerative Diseases.
Topics: Animals; Antioxidants; Biflavonoids; Caffeine; Catechin; Glutamates; Herb-Drug Interactions; Humans; | 2018 |
Are coffee's alleged health protective effects real or artifact? The enduring disjunction between relevant experimental and observational evidence.
Topics: Artifacts; Caffeine; Cardiovascular Diseases; Coffee; Diabetes Mellitus, Type 2; Humans; Hypertensio | 2018 |
An outlook on the role of decaffeinated coffee in neurodegenerative diseases.
Topics: Beverages; Caffeine; Chlorogenic Acid; Coffee; Humans; Neurodegenerative Diseases | 2020 |
Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.
Topics: Animals; Caffeine; Humans; Models, Biological; Neurodegenerative Diseases; Neuroprotective Agents; P | 2014 |
Cocoa phytochemicals: recent advances in molecular mechanisms on health.
Topics: Animals; Biological Availability; Cacao; Caffeine; Cardiovascular Diseases; Diabetes Mellitus; Flavo | 2014 |
The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders.
Topics: Aging; Animals; Caffeine; Dietary Supplements; Humans; Mammals; Neurodegenerative Diseases; Theobrom | 2015 |
The perspective of caffeine and caffeine derived compounds in therapy.
Topics: Acetylcholinesterase; Alkaloids; Brain; Caffeine; Humans; Monoamine Oxidase; Neurodegenerative Disea | 2015 |
Molecular and pharmacodynamic interactions between caffeine and dopaminergic system.
Topics: Animals; Brain; Caffeine; Dopamine; Humans; Neurodegenerative Diseases; Receptors, Dopamine; Recepto | 2014 |
Health benefits of methylxanthines in neurodegenerative diseases.
Topics: Animals; Cacao; Caffeine; Coffee; Disease Models, Animal; Humans; Ilex paraguariensis; Meta-Analysis | 2017 |
Having a Coffee Break: The Impact of Caffeine Consumption on Microglia-Mediated Inflammation in Neurodegenerative Diseases.
Topics: Animals; Caffeine; Coffee; Humans; Inflammation; Microglia; Neurodegenerative Diseases; Receptor, Ad | 2017 |
Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.
Topics: Alzheimer Disease; Animals; Brain Injuries; Caffeine; Humans; Huntington Disease; Neurodegenerative | 2011 |
1 trial available for caffeine and Neurodegenerative Diseases
| Article | Year |
|---|---|
Caffeine and attentional control: improved and impaired performance in healthy older adults and Parkinson's disease according to task demands.
Topics: Aged; Caffeine; Cognition; Humans; Neurodegenerative Diseases; Parkinson Disease; Reaction Time | 2022 |
8 other studies available for caffeine and Neurodegenerative Diseases
| Article | Year |
|---|---|
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Caffeine; CHO Cells; | 2013 |
Methylxanthines Induce a Change in the AD/Neurodegeneration-Linked Lipid Profile in Neuroblastoma Cells.
Topics: Alzheimer Disease; Caffeine; Cell Line, Tumor; Cholesterol; Humans; Lipids; Neural Stem Cells; Neuro | 2022 |
Tonic REM sleep muscle activity is the strongest predictor of phenoconversion risk to neurodegenerative disease in isolated REM sleep behaviour disorder.
Topics: Caffeine; Electromyography; Humans; Muscle Hypotonia; Muscle, Skeletal; Neurodegenerative Diseases; | 2023 |
Tonic REM sleep muscle activity is the strongest predictor of phenoconversion risk to neurodegenerative disease in isolated REM sleep behaviour disorder.
Topics: Caffeine; Electromyography; Humans; Muscle Hypotonia; Muscle, Skeletal; Neurodegenerative Diseases; | 2023 |
Tonic REM sleep muscle activity is the strongest predictor of phenoconversion risk to neurodegenerative disease in isolated REM sleep behaviour disorder.
Topics: Caffeine; Electromyography; Humans; Muscle Hypotonia; Muscle, Skeletal; Neurodegenerative Diseases; | 2023 |
Tonic REM sleep muscle activity is the strongest predictor of phenoconversion risk to neurodegenerative disease in isolated REM sleep behaviour disorder.
Topics: Caffeine; Electromyography; Humans; Muscle Hypotonia; Muscle, Skeletal; Neurodegenerative Diseases; | 2023 |
Caffeine prevents neurodegeneration and behavioral alterations in a mice model of agitated depression.
Topics: Animals; Behavior, Animal; Brain; Caffeine; Central Nervous System Stimulants; Depression; Gliosis; | 2020 |
The Medicinal Chemistry of Caffeine.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Caffeine; Chemistry, Pharmaceutical; Glycogen Phosphorylase; Hu | 2021 |
Simultaneous tonic and phasic REM sleep without atonia best predicts early phenoconversion to neurodegenerative disease in idiopathic REM sleep behavior disorder.
Topics: Aged; alpha-Synuclein; Biomarkers; Caffeine; Data Collection; Female; Humans; Male; Middle Aged; Mus | 2019 |
Therapeutic opportunities for caffeine in Alzheimer's disease and other neurodegenerative disorders.
Topics: Alzheimer Disease; Caffeine; Humans; Neurodegenerative Diseases; Phosphodiesterase Inhibitors | 2010 |
8-Aryl- and alkyloxycaffeine analogues as inhibitors of monoamine oxidase.
Topics: Alkylation; Animals; Binding Sites; Caffeine; Halogens; Humans; Inhibitory Concentration 50; Kinetic | 2011 |